Zeiss Medical Technology has announced that its Clarus 700 fundus imaging system has received official approval from the National Medical Products Administration (NMPA) in China, marking a significant development for retinal diagnostics in the region.
The Zeiss Clarus 700 offers high-resolution, ultra-widefield imaging in true color, enhancing the diagnostic capabilities of eye care professionals in China. The device is designed to seamlessly integrate into clinical workflows, supporting more accurate diagnoses and improved long-term vision preservation for patients.
Equipped with fluorescein angiography (FA), the Clarus 700 provides detailed imaging from the macular region to the extreme retinal periphery. This integration of FA with true-color imaging allows for a more complete and efficient assessment of retinal health.
“Zeiss Clarus 700 represents a major step forward in retinal imaging,” said Anuj Kalra, Head of Chronic Disease Management at Zeiss Medical Technology. “By seamlessly integrating ultra-widefield fluorescein angiography imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization, enhancing efficiency and supporting precise decision-making within the Zeiss Retina Workflow.”
The Zeiss Clarus 700 captures 133° in a single image and up to 267° with multiple captures, offering comprehensive views of the retina. The system features several advanced technologies to support clinical efficiency:
• Fluorescein Angiography and Live Infrared Imaging: For enhanced visualization of retinal pathologies.
• PrecisionFocus: Allows rapid targeting of regions of interest with sharp detail.
• QuickCompare: Facilitates comparison of pathology changes across patient visits.
• AutoBright: Automatically optimizes image brightness, enabling ophthalmologists to focus more on analysis and less on adjustments.